Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 4;12(1):e055314.
doi: 10.1136/bmjopen-2021-055314.

Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial

Ibrahim Ibrahim  1 , Hala Abdullahi  2 , Yassin Fagier  2 , Osman Ortashi  2 , Annalisa Terrangera  3 , Gbemisola Okunoye  2
Affiliations

Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial

Ibrahim Ibrahim et al. BMJ Open. .

Abstract

Introduction: Gestational diabetes mellitus (GDM) affects 23.6% of Qatari women and is associated with maternal and perinatal morbidity and long-term risk of developing type 2 diabetes. A number of challenges exist with current interventions, including non-compliance with dietary advice, the reluctance of mothers to ingest metformin tablets or use insulin injections. These challenges highlight the importance of pursuing evidence-based prevention strategies. Myo-inositol is readily available as an US Food and Drug Administration-approved food supplement with emerging but limited evidence suggesting it may be beneficial in reducing the incidence of GDM. Further studies, such as this one, from different ethnic contexts and with differing risk factors, are urgently needed to assess myo-inositol effects on maternal and neonatal outcomes.

Methods and analysis: This study is a prospective, randomised, double-blinded, placebo controlled clinical trial to either myo-inositol supplementation or placebo.We plan to enrol 640 pregnant women attending antenatal care at Sidra Medicine, Doha, Qatar, 320 in each arm. All participants will complete at least 12 weeks of supplementation prior to undertaking the Oral Glucose Tolerance Test at 24-28 weeks. The daily use of the trial supplementation will continue until the end of pregnancy. All outcome measures will be collected from the electronic medical records.

Ethics and dissemination: Ethical approval for the study was obtained on 12 April 2021 from Sidra Medicine (IRB number 1538656). Results of the primary trial outcome and secondary endpoints will be submitted for publication in a peer-reviewed journal.

Trial registration number: Prospectively registered on 26 May 2021. Registration number ISRCTN16448440 (ISRCTN registry).

Keywords: diabetes in pregnancy; maternal medicine; nutrition & dietetics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485–91. 10.1172/JCI200524531 - DOI - PMC - PubMed
    1. Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–81. 10.1016/j.diabres.2018.02.023 - DOI - PubMed
    1. Bashir M, Abdel-Rahman ME, Aboulfotouh M, et al. Prevalence of newly detected diabetes in pregnancy in Qatar, using universal screening. PLoS One 2018;13:e0201247. 10.1371/journal.pone.0201247 - DOI - PMC - PubMed
    1. HAPO Group THSCR . Hyperglycemia and adverse pregnancy outcomes. N Engl J Med Overseas Ed 2008;358:1991–2002. 10.1056/NEJMoa0707943 - DOI - PubMed
    1. Farrar D. Hyperglycemia in pregnancy: prevalence, impact, and management challenges. Int J Womens Health 2016;8:519–27. 10.2147/IJWH.S102117 - DOI - PMC - PubMed

Publication types

Associated data